Pregnancy and contraceptive use among women participating in the FEM-PrEP trial
Data from the FEM-PrEP trial was analyzed to evaluate contraceptive use, pregnancy incidence, and study drug adherence by contraceptive method. The results found that women using combined oral contraceptives, particularly new users, were more likely to become pregnant and less likely to adhere to study product than injectable users.
Resource Details
- Study Type
- Observational study
- Year
- 2015
- Population
- HIV-uninfected women
- Author
- Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D
More Publications & Resources
PrEP including LEN Counselling Guide for PBFP
LEN Learning Clinic 2: Clinical Considerations for the Implementation of LEN
Kenya Integrated Guidelines for Prevention, Treatment and Management of HIV, Sexually Transmitted Infections and Viral Hepatitis, 2026
Providing PrEP to Pregnant and Breastfeeding Women
Clinical Practice Guidelines for Providing PrEP for Pregnant and Breastfeeding Populations
Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis
PrEP and PEP Guidelines-Zambia
PrEP Lenacapavir Implementation Guidelines
Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics
No results found.